

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: Syngenta Investment Corp.

Application No./Patent No.: 09/730,525 Filed/Issue Date: Dec. 5, 2000

Entitled: Herbicide-tolerant Protox Genes Produced by DNA Shuffling

Syngenta Investment Corp., a Corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or

2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %
in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

2. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____
The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.
[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

09/24/03
Date
919-541-8666
Telephone number

Larry Stults
Typed or printed name
[Signature]
Signature

Head of IP & Licensing US and Plant
Title Science

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ASSIGNMENT

Whereas, Novartis AG, Lichtstrasse 35, 4002 Basel/BS, Switzerland, a corporation of Switzerland, is the assignee and legal owner of the entire right, title and interest in each of United States Patents 6,023,012, 6,084,155 and 6,308,458; and


Whereas, Novartis AG wishes to assign its entire interest in each of United States Patents 6,023,012, 6,084,155 and 6,308,458 to Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, and said Novartis Finance Corporation wishes to acquire Novartis AG's interest in said patents.

Now, therefore, Novartis AG hereby assigns to Novartis Finance Corporation and its successors and assigns its entire right, title and interest in (a) each of United States Patents 6,023,012, 6,084,155 and 6,308,458, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis AG to Novartis Finance Corporation constituting the entire right, title and interest in said patents (including reissue patents), extensions and reexamination certificates.


In witness whereof, Novartis AG has caused this Assignment to be signed by its duly authorized corporate signatories.

Signed this 22nd day of January 2003.

Novartis AG



Arthur Canonica
Patent- and Trademark
Administrator



Christoph Heid
Patent- and Trademark
Administrator

ASSIGNMENT

Whereas, Novartis Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of United States Patents 5,767,373, 5,939,602, 6,177,245, 6,282,837, 6,288,306 and 6,307,129, abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and pending United States Patent Application Nos. 09/196,019 and 09/730,917;

Whereas, Novartis Corporation was formerly known as Ciba-Geigy Corporation, the change of name having been recorded in the Patent and Trademark Office on October 13, 1998 (Reel 9507, Frames 0112-0114); and

Whereas, in accordance with a resolution of the Board of Directors of Ciba-Geigy Corporation (now Novartis Corporation) made on December 20, 1996, Novartis Corporation wishes to assign its entire interest in each of United States Patents 5,767,373, 5,939,602, 6,177,245, 6,282,837, 6,288,306 and 6,307,129, abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and pending United States Patent Application Nos. 09/196,019 and 09/730,917 to Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, and said Novartis Finance Corporation wishes to acquire Novartis Corporation's interest in said patents and abandoned and pending patent applications.


Now, therefore, Novartis Corporation hereby assigns to Novartis Finance Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of United States Patents 5,767,373, 5,939,602, 6,177,245, 6,282,837, 6,288,306 and 6,307,129, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), (2) abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and (3) (a) United States Patent Application Nos. 09/196,019 and 09/730,917, (b) any and all continuations and divisions of said application (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations), (c) any and all patents that may be issued and/or granted on all of said applications, (d) any and all applications for reissues of said patents, (e) any and all reissues of said patents that may be issued and/or granted, (f) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (g) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (3), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Corporation to Novartis Finance

Corporation constituting the entire right, title and interest in said patents (including reissue patents), abandoned applications, pending application, extensions and reexamination certificates.

In witness whereof, Novartis Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 23rd day of January 2003.

Novartis Corporation



Thomas Hoxie
Vice-President

ASSIGNMENT

Whereas, Novartis Finance Corporation, 608 Fifth Avenue, New York, NY 10020, a corporation of New York, is the assignee and legal owner of the entire right, title and interest in each of United States Patents 5,767,373, 5,939,602, 6,023,012, 6,084,155, 6,177,245, 6,282,837, 6,288,306, 6,307,129 and 6,308,458, abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and pending United States Patent Application Nos. 09/196,019 and 09/730,917; and

Whereas, in accordance with a resolution of its Board of Directors made on October 31, 2000, Novartis Finance Corporation wishes to assign its entire interest in each of United States Patents 5,767,373, 5,939,602, 6,023,012, 6,084,155, 6,177,245, 6,282,837, 6,288,306, 6,307,129 and 6,308,458, abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and pending United States Patent Application Nos. 09/196,019 and 09/730,917 to Syngenta Investment Corporation, 2200 Concord Pike, Wilmington, DE 19803, a corporation of Delaware, and said Syngenta Investment Corporation wishes to acquire Novartis Finance Corporation's interest in said patents and abandoned and pending patent applications.

Now, therefore, Novartis Finance Corporation hereby assigns to Syngenta Investment Corporation and its successors and assigns its entire right, title and interest in (1) (a) each of United States Patents 5,767,373, 5,939,602, 6,023,012, 6,084,155, 6,177,245, 6,282,837, 6,288,306, 6,307,129 and 6,308,458, (b) any and all applications for reissues of said patents, (c) any and all reissues of said patents that may be issued and/or granted, (d) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (e) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), (2) abandoned United States Patent Application Nos. 08/261,198, 09/038,878, 09/059,164, 09/198,794 and 09/451,650 and (3) (a) United States Patent Application Nos. 09/196,019 and 09/730,917, (b) any and all continuations and divisions of said application (including further continuations and divisions such as, but not limited to, continuations and divisions of continuations), (c) any and all patents that may be issued and/or granted on all of said applications, (d) any and all applications for reissues of said patents, (e) any and all reissues of said patents that may be issued and/or granted, (f) any and all applications for extensions of said patents (including reissue patents) and for reexamination certificates for said patents (including reissue patents) and (g) any and all extensions of said patents (including reissue patents) that may be issued and/or granted and reexamination certificates that may be issued for said patents (including reissue patents), including, in the case of all patents (including reissue patents) within the scopes of (1) and (3), the right to sue, and to obtain damages, for past infringement, said right, title and interest conveyed herein by Novartis Finance Corporation to Syngenta Investment Corporation constituting the entire right, title and interest in said patents (including reissue patents), abandoned applications, pending application, extensions and reexamination certificates.

In witness whereof, Novartis Finance Corporation has caused this Assignment to be signed by its duly authorized corporate officer.

Signed this 29th day of January 2003.

Novartis Finance Corporation

Wayne P. Merkelson
Wayne P. Merkelson
Vice-President

ASSIGNMENT

We,

Eric R. Ward	residing at	3761 Bentley Drive Durham, North Carolina 27707
Sandra L. Volrath	residing at	4225 Pin Oak Drive Durham, North Carolina 27707
Marie A. Johnson	residing at	4528 Dawn Road Gibsonia, PA 15044
Sharon L. Potter	residing at	3054 Cornwallis Road Research Triangle Park, NC 27709

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Syngenta Investment Corporation**, a Delaware corporation, having a place of business at 2200 Concord Pike, Wilmington, DE 19803, its successors, assigns and legal representatives, all our right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention entitled:

HERBICIDE-TOLERANT PROTOPORPHYRINOGEN OXIDASE ("PROTOX") GENES

invented by us and described in the application for United States Letters Patent

Application No. 09/102,419, filed on June 22, 1998

including (1) said application for United States Letters Patent and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said Syngenta Investment Corporation and its successors and assigns to

the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made;

And we hereby agree to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this day of , 2003 by Eric R. Ward

Signed this day of , 2003 by Sandra L. Volrath

Signed this 22nd day of January , 2003 by Marie A. Johnson
Marie A. Johnson

Signed this day of , 2003 by Sharon L. Potter

ASSIGNMENT

We,

Eric R. Ward	residing at	3761 Bentley Drive Durham, North Carolina 27707
Sandra L. Volrath	residing at	4225 Pin Oak Drive Durham, North Carolina 27707
Marie A. Johnson	residing at	4528 Dawn Road Gibsonia, PA 15044
Sharon L. Potter	residing at	3054 Cornwallis Road Research Triangle Park, NC 27709

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Syngenta Investment Corporation**, a Delaware corporation, having a place of business at 2200 Concord Pike, Wilmington, DE 19803, its successors, assigns and legal representatives, all our right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention entitled:

HERBICIDE-TOLERANT PROTOPORPHYRINOGEN OXIDASE ("PROTOX") GENES

invented by us and described in the application for United States Letters Patent

Application No. 09/102,419, filed on June 22, 1998

including (1) said application for United States Letters Patent and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said Syngenta Investment Corporation and its successors and assigns to

the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made;

And we hereby agree to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this day of , 2003 by Eric R. Ward

Signed this 11th day of FEBRUARY, 2003 by Sandra L. Volrath
Sandra L. Volrath

Signed this day of , 2003 by Marie A. Johnson

Signed this day of , 2003 by Sharon L. Potter

ASSIGNMENT

We,

Eric R. Ward	residing at	3761 Bentley Drive Durham, North Carolina 27707
Sandra L. Volrath	residing at	4225 Pin Oak Drive Durham, North Carolina 27707
Marie A. Johnson	residing at	4528 Dawn Road Gibsonia, PA 15044
Sharon L. Potter	residing at	3054 Cornwallis Road Research Triangle Park, NC 27709

for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, do hereby sell and assign to **Syngenta Investment Corporation**, a Delaware corporation, having a place of business at 2200 Concord Pike, Wilmington, DE 19803, its successors, assigns and legal representatives, all our right, title and interest, which includes the right to and full benefit of such priorities as may now or hereafter be granted to us by local laws or by treaty, including any international convention for the protection of industrial property, in and for the United States and its territories and possessions in and to the invention entitled:

HERBICIDE-TOLERANT PROTOPORPHYRINOGEN OXIDASE ("PROTOX") GENES

invented by us and described in the application for United States Letters Patent

Application No. 09/102,419, filed on June 22, 1998

including (1) said application for United States Letters Patent and all continuations and divisions thereof (including further continuations and divisions such as, but not limited to, continuations of continuations and divisions of continuations), (2) all United States Letters Patent which may be issued and/or granted on all such applications, (3) all applications for reissues and extensions of and reexamination certificates for all such United States Letters Patent and (4) all reissues and extensions and reexamination certificates issued for all such United States Letters Patent, the said interest being the entire ownership of said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates to be held and enjoyed by the said Syngenta Investment Corporation and its successors and assigns to

the full end of the terms to which said United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates may be granted and/or issued, as fully and entirely as the same would have been held and enjoyed by us if this sale, assignment and transfer had not been made;

And we hereby agree to sign and/or execute any further documents and/or instruments which may be necessary, lawful and proper in and/or for the filing and/or prosecution of said applications for United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates and/or the granting and/or issuance thereof and/or to otherwise secure title to said invention and all of said applications, United States Letters Patent (including reissue Letters Patent), extensions and reexamination certificates in said assignee.

Signed this 22nd day of January, 2003

by



Eric R. Ward

Signed this 13th day of

, 2003

by

Sandra L. Volrath

Signed this

day of


, 2003

by

Marie A. Johnson

Signed this 13th day of February, 2003

by


Sharon L. Potter